These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 11765303

  • 21. Amiodarone versus sotalol for atrial fibrillation.
    Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD, Raisch DW, Ezekowitz MD, Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators.
    N Engl J Med; 2005 May 05; 352(18):1861-72. PubMed ID: 15872201
    [Abstract] [Full Text] [Related]

  • 22. Class III antiarrhythmic agents: the next wave.
    Bauman JL.
    Pharmacotherapy; 1997 May 05; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [Abstract] [Full Text] [Related]

  • 23. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J.
    Europace; 2000 Jul 05; 1 Suppl C():C10-5. PubMed ID: 11220519
    [Abstract] [Full Text] [Related]

  • 24. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI.
    Cleve Clin J Med; 2001 Apr 05; 68(4):353-63. PubMed ID: 11326815
    [Abstract] [Full Text] [Related]

  • 25. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R, Sami M.
    Can J Cardiol; 2001 Jan 05; 17(1):63-7. PubMed ID: 11173316
    [Abstract] [Full Text] [Related]

  • 26. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN.
    Card Electrophysiol Rev; 2003 Sep 05; 7(3):225-8. PubMed ID: 14739718
    [Abstract] [Full Text] [Related]

  • 27. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL, Hilleman DE.
    Pharmacotherapy; 2000 Jul 05; 20(7):776-86. PubMed ID: 10907968
    [Abstract] [Full Text] [Related]

  • 28. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H, Brendorp B, Pedersen OD, Køber L, Torp-Petersen C.
    Expert Opin Pharmacother; 2003 Jun 05; 4(6):973-85. PubMed ID: 12783593
    [Abstract] [Full Text] [Related]

  • 29. Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation.
    Hohnloser SH.
    Pacing Clin Electrophysiol; 1994 May 05; 17(5 Pt 2):1019-25. PubMed ID: 7518589
    [Abstract] [Full Text] [Related]

  • 30. Antiarrhythmic drug therapy in the treatment of atrial fibrillation.
    Jung F, DiMarco JP.
    Cardiol Clin; 1996 Nov 05; 14(4):507-20. PubMed ID: 8950053
    [Abstract] [Full Text] [Related]

  • 31. The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.
    Derakhchan K, Villemaire C, Talajic M, Nattel S.
    Cardiovasc Res; 2001 Apr 05; 50(1):75-84. PubMed ID: 11282080
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Milan DJ, Saul JP, Somberg JC, Molnar J.
    Cardiology; 2017 Apr 05; 136(1):52-60. PubMed ID: 27554842
    [Abstract] [Full Text] [Related]

  • 33. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA, Kluger J, White CM.
    Pharmacotherapy; 2007 Sep 05; 27(9):1297-305. PubMed ID: 17723083
    [Abstract] [Full Text] [Related]

  • 34. New advances in class III antiarrhythmic drug therapy.
    Sager PT.
    Curr Opin Cardiol; 2000 Jan 05; 15(1):41-53. PubMed ID: 10666660
    [Abstract] [Full Text] [Related]

  • 35. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR, Marinchak RA, Rials SJ, Bharucha D.
    Am J Cardiol; 1997 Oct 23; 80(8A):16G-23G. PubMed ID: 9354408
    [Abstract] [Full Text] [Related]

  • 36. Sotalol: An important new antiarrhythmic.
    Anderson JL, Prystowsky EN.
    Am Heart J; 1999 Mar 23; 137(3):388-409. PubMed ID: 10047618
    [Abstract] [Full Text] [Related]

  • 37. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A, Vichiendilokkul A, Racine E, Milad A.
    Am J Health Syst Pharm; 2001 Nov 01; 58(21):2050-9. PubMed ID: 11715827
    [Abstract] [Full Text] [Related]

  • 38. New antiarrhythmic drugs for the treatment of atrial fibrillation.
    Castro A, Bianconi L, Santini M.
    Pacing Clin Electrophysiol; 2002 Feb 01; 25(2):249-59. PubMed ID: 11916001
    [No Abstract] [Full Text] [Related]

  • 39. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
    LaPointe NM, Pamer CA, Kramer JM.
    Pharmacotherapy; 2003 Oct 01; 23(10):1316-21. PubMed ID: 14594348
    [Abstract] [Full Text] [Related]

  • 40. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F, Candinas R, Frielingsdorf J.
    Herz; 1993 Feb 01; 18(1):20-6. PubMed ID: 8454249
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.